ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-OR107

Resistant Hypertension Potentiates the Risk of ESRD in African Americans in the Million Veteran Program (MVP)

Session Information

Category: Hypertension and CVD

  • 1401 Hypertension and CVD: Epidemiology, Risk Factors, and Prevention

Authors

  • Akwo, Elvis A., Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Robinson-Cohen, Cassianne, Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Wilson, Peter W., Emory University, Atlanta, Georgia, United States
  • O'Donnell, Christopher Joseph, Boston Veterans Administration, Boston, Massachusetts, United States
  • Edwards, Todd L., Vanderbilt University Medical Center, Nashville, Tennessee, United States
  • Kovesdy, Csaba P., University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Hung, Adriana, VA & Vanderbilt University, Nashville, Tennessee, United States
Background

African Americans (AAs) are 4 times as likely as Whites to develop ESRD. Resistant hypertension (RH), a severe form of hypertension (HTN) is associated with increased risk of cardiovascular (CV) and renal outcomes. We investigated how ESRD risk is modified by race.

Methods

We designed a retrospective cohort of 240,038 veterans with HTN, enrolled in the MVP with a GFR >30 ml/min. The primary exposure was incident RH (time-varying). The primary outcome was incident ESRD during a 13.5 yr follow up: 2004-2017. Secondary outcomes were myocardial infarction (MI), stroke, and death. Incident RH was defined as failure to achieve outpatient BP <140/90 mmHg with 3 anti-HTN drugs, including a thiazide, or use of ≥4 drugs, excluding BPs when pain score was >5, when interfering medications or secondary HTN were present. Poisson models were used to estimate incidence rates (IR) and test biologic interaction with race. Cox (and competing-risks) models were used to identify independent effects.

Results

Median age was 60 yrs; 20% were African American and 6% were women with 23,385 incident RH cases (9.7%). RH patients had higher IR (per 1000 PY) of ESRD (4.5 vs. 1.3), MI (6.5 vs 3), stroke (16.4 vs 7.6) and death (12 vs 6.9) than non-resistant HTN (NRH). In Cox models adjusted for traditional CV risk factors; RH patients had a 2.0, 1.67, 1.9 and 1.14-fold higher risk of ESRD, MI, stroke, and death, respectively. In Poisson models, AAs with RH had a 2.5-fold higher risk of ESRD compared to AAs with NRH; 3-fold the risk of Whites with RH, and 9-fold the risk of Whites with NRH [p-interaction < 0.01].

Conclusion

RH was associated with a higher risk of ESRD (and CV outcomes), especially in AAs. Interventions (behavioral, drug choices) that improve reaching BP targets in RH patients, could have a major impact on ESRD incidence in this high-risk population, particularly in AAs.

Funding

  • Veterans Affairs Support